Renalytix

Update in progress

RENX.L (LSE)

Company RatingNeutral
SectorHealthcare
IndustryHealth Information Services

Renalytix Plc develops AI-enabled in vitro diagnostic solutions for kidney disease management in Europe and the United States. Its KidneyIntelX platform combines validated biomarkers, genetics, and electronic health record data with an AI algorithm to generate a personalized patient risk score. Uses include diagnosis, prognosis, trial patient stratification, and drug discovery. Licensed with Mount Sinai for AI-driven diagnosis. Founded 2018, based in London.

Company score

Sentiment: 0.40; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.51; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.18; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.29; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive